This month saw the PTAB issue the final decision on a Kyle Bass inter partes review. Michael Loney asks whether that’s the last we’ll see of Bass at the Board and analyses the legacy of his campaign against pharmaceutical patents
Unlock this content.
The content you are trying to view is exclusive to our subscribers.
The England and Wales appeals court handed down its judgment just seven working days after hearing the trademark dispute involving pharma company Merck
Penelope Aspinall, of IP wellbeing charity Jonathan’s Voice, explains why managers should take a three-tiered approach to looking after workers’ mental health